Navigation Links
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint
Date:8/24/2011

SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).  Preliminary analysis demonstrates that the trial did not achieve statistical significance for the primary endpoint, six-minute walk distance (6MWD) at Week 16.

The FREEDOM-C(2) trial was a randomized, double-blind, placebo-controlled trial of patients with PAH, a chronic, life-threatening illness.  The study population consisted of 310 patients who were optimized on an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or both.  In addition to one of these oral therapy regimens, patients were administered oral treprostinil or placebo twice daily with the dose titrated (increased to tolerability) over the 16-week trial.  The majority (~73%) of patients were World Health Organization (WHO) Class III patients of varied etiologies, including idiopathic or familial PAH (~65%), collagen vascular disease associated PAH (~31%), and PAH associated with HIV or other associated conditions (~3%).  Mean baseline walk distance was approximately 333 meters.

The primary efficacy endpoint of the trial was the median change in 6MWD at 16 weeks relative to baseline.  With regard to the primary efficacy results, the placebo-corrected median change in 6MWD at Week 16 was 10 meters (p=0.089, Hodges-Lehmann estimate and non-parametric analysis of covariance in accordance with the trial's pre-specified statistical analysis plan).

Overall, 132 (84%) oral treprostinil and 138 (90%) placebo patients completed Week 16 with an average dose of 3.0 plus or minus 1.9 mg twi
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
11. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... This is a professional and in-depth ... The report provides basic biocides information, including its ... well as industry overview. This research covers the ... well as Global industry analysis covering macroeconomic environment ... Chinese biocides industry covers information on ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/31/2014)... , Oct. 31, 2014  Atlanta-based Intellimedix could ... accompanying the onset of Ebola by suggesting a ... at Georgia Tech,s Center for Computational Systems Biology ... to find alternative uses for existing drugs through ... to aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... - Taking more women-owned businesses to the $1 million annual ... perhaps none more important than information technology. , ,That was ... Wisconsin Make Mine a Million program, where women-owned ... extent in their quest to reach the $1 million mark. ...
... Editor's note: Attorney Greg Lynch, a partner with ... on this article with Laura Riske, the firm's director of ... - The United States Department of Energy has ... , ,This funding opportunity is open to applicants with projects ...
... - MailFoundry , a Green Bay anti-spam solution provider, ... 100,000 users and 20 million e-mails per day. , ,The ... this week's Interop exhibit in Las Vegas. , ,The series ... attacks, viruses, and botnets. It comes with MessageIQ 3.0, the ...
Cached Biology Technology:Learning from the big boys: With technology, women urged to go gradual 2Learning from the big boys: With technology, women urged to go gradual 3Wisconsin applicants urged to pursue DOE funding for cellulosic biomass 2
(Date:10/29/2014)... Plants rely on sunlight to make their food, but they ... do. Recently, scientists discovered a group of molecules in plants ... in the Journal of the American Chemical Society , ... plant sunscreens work. , Timothy Zwier and colleagues at Purdue ... to daily can cause serious damage to plant DNA and, ...
(Date:10/29/2014)... all the rage. Thousands of scientists worldwide are conducting ... titanium dioxide nanoparticles from sun creams can get through ... from electronic products are as hazardous for the lungs ... food can get into the blood via the intestinal ... are flowing – and the number of scientific projects ...
(Date:10/29/2014)... bodies decompose, their types and numbers of bugs ... could mean the difference between a closed case ... is using a more than $866,000 U.S. Department ... examine these changing populations. The microbial communities may ... death, gender, race, socioeconomic relations and more, said ...
Breaking Biology News(10 mins):Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3MSU partners with Detroit to investigate death scenes 2
... is closely tied to its sexual habits, ecologists have ... such intimate relationships between plants and pollinators, the study ... published online in the British Ecological Society,s journal Functional ... in certain bumblebee species found in the shrinking areas ...
... . Over the past decades climate change ... given rise to a growing scientific interest in the ... dominate our energy map are not only becoming scarce, ... Within the field of renewable energies the scientific community ...
... IMMEDIATE RELEASE Fighting global warming at ... Substituting chicken, fish, or vegetables for red meat ... even more dramatically than buying locally sourced food, ... impacts of food production and distribution in the United ...
Cached Biology News:Ecologists tease out private lives of plants and their pollinators 2More efficient fuel-cells, thanks to a new catalyst 2More efficient fuel-cells, thanks to a new catalyst 3More efficient fuel-cells, thanks to a new catalyst 4American Chemical Society's Weekly PressPac -- April 30, 2008 2American Chemical Society's Weekly PressPac -- April 30, 2008 3American Chemical Society's Weekly PressPac -- April 30, 2008 4American Chemical Society's Weekly PressPac -- April 30, 2008 5American Chemical Society's Weekly PressPac -- April 30, 2008 6American Chemical Society's Weekly PressPac -- April 30, 2008 7American Chemical Society's Weekly PressPac -- April 30, 2008 8
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... first identified as the cellular homolog of the ... Jun D have been shown to be almost ... are involved in dimerization and DNA binding, whereas ... activation, diverge. Antigen: The ...
...
... (phospho Y1007) ( Abpromise for ... Antigen: Synthesized phosphopeptide derived from ... of tyrosine 1007 (K-E-Y P -Y-K). ... 3717 Swiss ...
Biology Products: